An analysis of the secondary endpoint of the phase III CONDOR study showed PSMA scans had a profound impact on patient care.
Results from the phase III CONDOR trial, presented during the 2020 ASCO Virtual Scientific Program, showed that prostate specific membrane antigen (PSMA) 18F-DCFPyL-positron emission tomography (PET) scans demonstrated a correct localization rate (CLR) of 84.8-87.0% per 3 blinded independent readers, meeting the trial’s primary endpoint.
In an interview with CancerNetwork, Michael J. Morris, MD, prostate cancer section head at Memorial Sloan Kettering Cancer Center discussed a secondary endpoint of the trial – the change in treatment plans and patient care after completion of the scans.
So, the clinicians completed a questionnaire both before and after the performance of the PSMA scan to see if the PSMA scan changed their management. In 20% of those patients, that change in management was a change in goal of care, from a non-curative systemic therapy-based treatment to a potentially curative salvage local therapy-based treatment. So, these were not insignificant changes that were made as a result of the PSMA scan. And around 64% of the patients overall had a change in treatment plan after getting the PyL scan. So, I think what it shows you is not just from a performance characteristic standpoint that the scan was good, with a CLR in the 80-90% range, but that also, the clinician took away from that, that the information was reliable enough to act on, acted on it, and made significant changes to the patient's treatment plan as a result. So, it's not only a good study, but it's a study that clinicians can rely on for clinically significant information in order to change their treatment.
Related Content:ASCO Prostate Cancer